[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624221":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":44,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Fujian Medical University Union Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(ICG group) receiving VATS with near-infrared-indocyanine green fluorescence for RLN visualization","EXPERIMENTAL",null,[13],"Drug: ICG (Indocyanine Green)",{"label":15,"type":16,"description":11,"interventionNames":11},"(Control group) receiving VATS without near-infrared-indocyanine green fluorescence for RLN visualiz","NO_INTERVENTION",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","ICG (Indocyanine Green)","Minimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the recurrent laryngeal nerve.",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Bin Zheng","CONTACT","15959002753","lacustrian@163.com",[30],{"facility":5,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Fuzhou","Fujian","350000","China","CN",{"type":37,"coordinates":38},"Point",[39,40],119.30611,26.06139,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100624221","phase-3-the-value-of-near-infrared-fluorescence-imaging-in-the-protection-of-the-recurrent-laryngeal-nerve-during-minimally-invasive-esophagectomy-100624221",false,"NCT07406815","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy","The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy：A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years at the time of diagnosis (excluding 18 and 75);\n* Preoperative biopsy pathology confirming esophageal cancer;\n* Undergoing elective thoracoscopic esophageal cancer radical surgery with intraoperative anastomosis;\n* Tolerable heart, lung, liver, and kidney function for surgery;\n* Patients and their families are able to understand and willing to participate in this clinical study, and have signed an informed consent form.\n\nExclusion Criteria:\n\n* Allergy to ICG or iodine;\n* History of neck or thoracic surgery;\n* Patients requiring emergency surgery;\n* Tumors involving adjacent organs necessitating combined organ resection;\n* Patients with tumor recurrence or distant metastasis;\n* Participation in or having participated in other clinical trials within 4 weeks prior to selection;\n* History of severe mental illness;\n* Pregnant or lactating women;\n* Patients with other conditions deemed unsuitable for participation by the investigator;\n* Intraoperative conversion to open thoracotomy.\n* Patients who, after assessment or intraoperative exploration, cannot undergo the planned surgery;\n* Patients who voluntarily withdraw from the study;\n* Patients with concomitant non-neoplastic conditions that prevent them from continuing with the study protocol;\n* Patients who, after enrollment in the study, are unable to complete it due to other reasons.","ALL","18 Years","75 Years",{"count":57,"type":58},144,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","The goal of this clinical trial is to learn whether the application of indocyanine green near-infrared imaging system can accurately locate the recurrent laryngeal nerve (RLN) during lymph node dissection in esophageal cancer radical surgery, thereby reducing the risk of RLN injury. The main questions it aims to answer are:\n\n1. Can preoperative intravenous administration of indocyanine green enable visualization of the RLN;\n2. Does performing RLN dissection guided by near-infrared imaging system reduce the probability of RLN injury, leading to better clearance of RLN lymph nodes and improved RLN protection rates? Researchers will compare whether indocyanine green was intravenously administered preoperatively to assess intraoperative RLN visualization. Participants in the study group will receive intravenous indocyanine green at a dose of 5mg\u002Fkg 24 hours before surgery. All patients will be monitored for RLN injury-related complications postoperatively, and RLN injury status will be objectively assessed via laryngoscopy one week post-operation.",[64,65,20,66],"Esophageal Cancer","Recurrent Laryngeal Nerve","Lymph Node Dissection","NOT_YET_RECRUITING","2026-02-05",{"date":70,"type":71},"2026-02-12","ACTUAL",{"date":73,"type":58},"2026-06-01",{"date":75,"type":58},"2028-06-01",{"name":5,"class":6},1]